FDA to Biosimilar Sponsors: Let’s Talk

June 13, 2018

Drug industry leaders now have a clearer path to meet with the Food and Drug Administration (FDA) to discuss how to speed up the approval process for cheaper copies of complex biologic drugs (83 Fed. Reg. 26,060).

Related Stories